Browse drugs

… as promising treatments for these conditions. T cell engagers (TCEs) provide a more direct and robust mechanism for targeting B cel…

…he combination strategy of relatlimab (anti-LAG-3 antibody) and nivolumab (anti-PD-1 antibody) approved at the beginning of 2024 as a fir…

… group has demonstrated that the histone deacetylase inhibitor, entinostat, decreases the immunosuppression by MDSCs, and when combined wi…

…ibitor (SHP2i) or its genetic ablation specifically in B cells (Cd79α-Cre; Ptpn11flfl ) disrupted the mutant KRAS-mediated Breg-inducing signals, cur…

…cumulation of immunosuppressive metabolites like lactic acid or adenosine. Consequently, the tumor microenvironment gradually erodes the …

…d that mice in which tumors were treated with cDC1s loaded with OVA could reject rechallenge with OVA-negative tumors. While this w…

…red with aAPCs and 10 ng/mL of hIL-2 in the presence of 1 uM of DON or vehicle. Characterization of antigen-specific cells was perf…

…tions BTN1A1 as a candidate immune evasion marker. Accordingly, BTN1A1 may serve as both a stratification biomarker and a therapeutic …

…eveloped Ly6G-PET, a novel, non-invasive imaging strategy using 89Zr-DFO-anti-Ly6G to detect and monitor gMDSCs in vivo. This approach enables lon…

…K Assay; and 21 patients with advanced ccRCC being treated with ipilimumab and nivolumab (ipi+nivo), assessed pre-treatment and prior to c…

…uded: ipilimumab/nivolumab (8/16), nivolumab/relatlimab (7/16), pembrolizumab (1/16). ctDNA change from baseline to 3–4 weeks was not signifi…

…metastases and extensive-stage disease. Despite the approval of tarlatamab and ongoing development of DLL3- or B7-H3-targeted ADCs, tumor …